Business
Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer
PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differenti
About this update from Transcenta Holding Limited
[{"type":"text","content":"PRINCETON, N.J. and SUZHOU, China, April 23, 2026 (GLOBE NEWSWIRE) -- Transcenta Therapeutics (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announced the presentation of preclinical data highlighting its proprietary LIV1-targeting antibody-drug conjugates (ADC) at the 2026 AACR Annual Meeting. The data demonstrate strong anti-tumor activity, differentiated payload-dependent efficacy, and favorable tolerability profiles, supporting further development in LIV1-positive solid tumors.","length":631,"tagName":"p"},{"type":"text","content":"LIV1 is a member of the zinc transporter family, with limited normal tissue expression, and is found to be overexpressed with high prevalence in breast (93%), prostate (72%) and lung (10%) cancers, making it an attractive cell surface target for developing ADC therapeutics.","length":274,"tagName":"p"},{"type":"text","content":"Transcenta Therapeutics has developed 48D6, a novel proprietary humanized anti-LIV1 monoclonal antibody with high affinity, specificity, and internalization capability. Using Retrogenix cell microarray technology, 48D6 demonstrated no non-specific interactions with other human proteins, confirming its high target specificity. Leveraging 48D6, Transcenta Therapeutics then generated two ADC candidates using a glycotransferase-mediated site-specific conjugation platform: ADC-2, conjugated with a Topoisomerase I inhibitor payload, and ADC-3, conjugated with MMAE.","length":565,"tagName":"p"},{"type":"text","content":"Pharmacokinetic studies in Balb/c mice showed that ADC-2 exhibited a half-life of approximately 10.4–11.6 days, significantly longer than that of a benchmark SGN-LIV1A analog (3.7–3.9 days), and comparable to the naked antibody 48D6 (13.8–15.6 days), indicating favorable in vivo stability.","length":290,"tagName":"p"},{"type":"text","content":"In vivo efficacy studies demonstrated that ADC-2 elicited potent anti-tumor activity in LIV1-expressing ER+/HER2- breast cancer and non-small cell lung cancer (NSCLC) patient-derived xenograft (PDX) models at a dose of 6 mg/kg administered once weekly for four weeks.","length":267,"tagName":"p"},{"type":"text","content":"For LIV1 expressing prostate PDX models, ADC-2 demonstrated lim...